Drug Combination Details
| General Information of the Combination (ID: C42889) | |||||
|---|---|---|---|---|---|
| Name | Toosendanin NP Info | + | Regorafenib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | DVL2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Phosphorylation | GSK-3B | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | STAT3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | WWOX | Molecule Info | |||
| In-vitro Model | MHCC97-L | CVCL_4973 | Adult hepatocellular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
TSN and RGF combination (TRC) synergistically inhibited the proliferation and migration of MHCC-97L cells. The upregulation of WWOX (WW-domain containing oxidoreductase) played a vital role in the HCC cell growth treated with TRC. | |||||
